Next-Generation
Immunoassay
Ultra-fast.
Ultra-sensitive.
Ultra-scalable.
Now.
Biocellis is transforming diagnostic testing with breakthrough immunoassay technology: results in under 60 seconds, with picogram-level sensitivity and minimal sample preparation. Based on patented research developed over a decade at leading French scientific institutions.
The Challenge
What if diagnostics were no longer the bottleneck?
Healthcare depends on timely information — but most rapid tests sacrifice sensitivity, and most sensitive tests take too long. In emergencies, during pandemics, or at scale, the world needs diagnostics that are both fast and precise. Sometimes, even a few seconds can make all the difference.
Biocellis is closing that gap.
A new generation
of bioluminescence
immunoassays
Our Solution
A new generation of bioluminescence immunoassays
Biocellis has developed a patented immunoassay platform that delivers laboratory-grade sensitivity in under 1 minute, using a compact, portable format ideal for point-of-care and high-throughput screening.
What it enables:
- Antigen detection for active infections
- Serological testing for immune response or exposure
- Testing in hospitals, clinics, airports, workplaces — anywhere
Key advantages:
- < 60 seconds to result
- Sensitivity down to picogram per milliliter level
- Scalable to mass population screening
Biocellis technology
was developed
through over
10 years of
interdisciplinary
research
Scientific Excellence
Biocellis technology was developed through over 10 years of interdisciplinary research at top-tier French research institutions (Institut Pasteur, CNRS, Inserm) and was chosen by Santé Publique France to perform over 1 million epidemiology tests for monitoring French population during COVID. It is protected by international patents and validated by a multidisciplinary team of physicists, biologists, and clinicians.
Our bioluminescence technology is also accessible for research and life sciences applications via Synthelis (www.synthelis.com), part of the Biocellis group.
Applications
From hospital labs to global health challenges
Biocellis’ platform is versatile and field-ready, with potential applications across multiple sectors:
Human health
Infectious diseases, immune monitoring
Veterinary diagnostics
Fast field diagnostics
Environmental health
Pathogen and biomarker detection
Food safety
Rapid contaminant screening
Public screening
Emergency triage, border control, mass events
About Us
Biocellis is a French deeptech startup based in Grenoble, France, pioneering a new generation of immunoassays that combine ultra-sensitivity with fast readouts. Our long-term vision: becoming a global leader in decentralized, high-throughput diagnostics—capable of responding rapidly to emerging biological threats.
Powered by rigorous science and designed for real-world impact, Biocellis was initially co-founded by Vincent Poher with Institut Pasteur and the leading scientists Thierry Rose and Sophie Goyard, aiming at turning the One Health mission into a tangible reality.
General inception joined the team as a strategic business partner in 2025. Biocellis has then become the mother company of Synthelis (www.synthelis.com) that is developing the Lifescience applications of the group’s technologies for cell-free protein expression and bioluminescence.
Latest news
Partner with Us
We’re looking for partners to bring this breakthrough to life.
Let’s collaborate on:
- Co-development of diagnostic applications
- Clinical validation
- Licensing and manufacturing
- Pilot testing in real-world settings
Get in touch
Let’s shape
the future
of diagnostics,
together.